Or­bital Ther­a­peu­tics clos­es South San Fran­cis­co lab, elim­i­nat­ing some roles

Or­bital Ther­a­peu­tics, a well-fund­ed biotech born out of buzzy base edit­ing com­pa­ny Beam Ther­a­peu­tics, has shut­tered its South San Fran­cis­co of­fice.

The start­up was un­veiled in April with a $270 mil­lion Se­ries A from ARCH Ven­ture Part­ners, a16z Bio + Health, and more than half a dozen oth­er in­vestors. The com­pa­ny is work­ing on RNA med­i­cines in­clud­ing vac­cines, pro­tein re­place­ment ther­a­pies and im­munomod­u­la­tors, with the first ex­pect­ed to en­ter the clin­ic with­in two to four years, CEO Giuseppe Cia­ramel­la told End­points News at the time.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER